Phase 1 Clinical Trials for Healthy Volunteers
First-in-human drug safety and dosing studies that compensate healthy adults.
There are 440 actively recruiting Phase 1 clinical trials enrolling healthy volunteers. Phase 1 studies test investigational drugs for safety and dosing in small groups under close medical supervision. Updated daily from ClinicalTrials.gov.
What is a Phase 1 trial?
Phase 1 is the first stage of human testing. A small group of healthy volunteers receives the investigational drug to evaluate safety, tolerability, and pharmacokinetics. Participants are monitored closely — often as inpatients at a clinical pharmacology unit — and compensated for their time. These studies are reviewed and approved by an ethics committee before enrollment begins.
Showing 21–40 of 440 Phase 1 studies
A Study of NHL907 in Healthy Adult Participants
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis
A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)
Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase Ⅰ
A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants
A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
SAR447971 First-in-human Study
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061
A Study to Exploratively Evaluate the Safety, Tolerability and Pharmacokinetics of DA-5223 Compared With DA-5223-R in Healthy Adult Subjects
A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
A Phase 1 Study of Single-Dose BW-50218 in Healthy Chinese Participants
Inhaled RB042 in Healthy Adult Volunteers and Healthy Adult Smokers
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
A Study of LY3867070 in Healthy Participants
A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
A Study of LY4088044 in Healthy Participants
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
Phase 1 FAQ
How much do Phase 1 trials pay?
Compensation varies by study duration and intensity. Inpatient Phase 1 studies (multi-day residential stays) typically pay $1,000–$5,000+. Outpatient studies with follow-up visits may pay $200–$1,500. Specific amounts are disclosed in the informed consent document.
Are Phase 1 trials safe?
Phase 1 trials carry some risk as participants receive an investigational drug. All studies are reviewed and approved by an ethics committee (IRB/HREC) before enrollment begins. Participants are monitored continuously and can withdraw at any time.
What happens during a Phase 1 study?
Typically you attend a screening visit, then either stay at the clinical unit (inpatient) or visit regularly (outpatient). Blood draws, vital signs, and other assessments are conducted at scheduled intervals. The study team monitors you throughout and provides meals and accommodation for inpatient stays.